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Ticlopidine Administration After Stent Placement: Frequency of Adverse
Reactions
R.J. Russo, K.M. Stevens, S.L. Norman, D.A. Cloutier, P.S.Teirstein.
Scrfpps Clinic, La Jolla, CA, USA
During a 13-month period (Januaty 1995 to January 1996), 682 patients un-
denvent Palmaz-Schatz coronary stent placement at Scripps Clinic and were
discharged on a variety of anticoagulation protocols, all of which included
ticlopidine (500 mg/day) for 1 month. Discharge medications were: Ticlid (T)
+ aspirin (ASA) 325 mg/day in 385 (56.5%) pts; T + ASA + enoxaparin (E)
60 mg/day in 228 (33.4%) pts; T + ASA + waffarin (W) in 93 (13.6%) pts;
and T + ASA + E + W in 18 (2.6%) pts. Patients were examined within 1
week of hospital discharge, a complete bled cell count was obtained at 2
weeks, and telephone follow-up was obtained at 1 month. Results: Adverse
effects were experienced by 29 (4.257.) pts during the 1 month of ticlopi-
dine administration and included rash in 13 (1.91%) pts, gastrointestinal (Gl)
distress in 6 (1.17%) pts, neutropenia (absolute neutrophil count [ANC] <
1500) in 5 (0.73%) pts, hives in 2 (0.29%) pts, and GI bleeding in 1 (0.15%)
pt. In 12 (1.76%) pts who experienced an adverse effect, ticlopidine was
tolerated for a full month after a reduction of dose to 250 mgfday. However,
17 (2.49%) pts required discontinuation of ticlopidine prior to 1 month due
to a medication adverse effect. indications for discontinuation were rash in
7 (1.03%) pts, GI distress in 6 (0.68%) pts, neutropenia (ANC < 1000) in
3 (0.44%) pts, and hives in 1 (0.15%) pt. The frequency of adverse effects
was similar for all anticoagulation protocols (T+ ASA, 4.25%; T + ASA + E,
4.0%; T + ASA + W. 2.220A;and T + ASA + E + W, 12.50/-:p = ns). No patient
experienced irreversible neutropenia. Conclusion: Ticlopidine therapy for 1
month after stent placement is associated with a low rate of adverse effects
which require either reduction of dose or discontinuation of medication.
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~771-21 lncidenceOfNeutropeni*atalThr~mb~~W~Penia
Associated With Ona Month of Ticlopidine Therapy
Post Coronary Stenting
G.Szto,S. Lewis, K. Punamiya, S. Jung, R. Landin, M. Ball, Z. Hodes,
D. Lips, J. Coverdala, T. Linnemeier. fVorfhsideCardio/ogx PC, Indiana
Heart lrrstitute, Indianapolis, IN, USA
Objective:The reported incidence of neutropenia (NTP) (absolute neutrophil
count [ANC] -=1200/ml) in patients (pts) on chronic ticlopidine (TIC) therapy
for TIAs is 2.4%. The incidence of NTP orthrombocyfopenia (TCP) with one
month TIC therapy post coronaty stenting has not been reported.
Methods: We prospectively studied complete blood counts (CBC) at 2,4,
and 6weeks on 340 consecutive pts treated with coronary stenting from 4/95
to 6/96. A total of 542 stents (463 Palmez-Schatz, 59 Gianturco-Roubin, 18
Multi-Link, 2 others) were placed in 353 lesions (mean 1.6 stentelpt). Mean
age was 61 * 11 yeara (males 70%). Adjunetive high pressure (>16 ATM)
balloon dilatation was performed in all pts. A total of 98% (333/340) of pts
were released on ASA, 100%.on TIC, with sub-Q heparin used in high risk
subsets.
Resu/ta:Neutropenia was deteeted in 4 pts (1.2%) with severe NTP (ANC
< 450/ml) in 2 of these 4 pts (0.67.). TCP was detected in 2 pts (0.6Yo)with
1 (0.3%) death from cerebral hemorrhage. TIC was discontinued in 4/340
(1.2%) pts before one month because of a reduction in ANC without stent
thrombosis. Subacute stent thrombosis occurred in 3/340 (0.9Yo)pts in the
cohort as a whole.
Conclusion: The incidence of serious NTP is 1.2%, fatal TCP 0.37. of
pts. A drop in ANC necessitating discontinuation of TIC occurred in 1.2%
of pts. Further studies using TIC for shorter duration have been initiated.
Meanwhile, pts receiving TIC for one month should continue to have aerial
monitoring of CBCS.
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Clopidogrel, A Novel Platelet ADP-Raceptor
Antagonist Inhibits Aspirin and
Ticlopidine-Rasistant Stent Thrombosis
R. Makkar, N. Eigler, S. Kaul, H. Zeng, J.-M. Herbert 1, F. Litvack.
Cedars-Sinai Medical Cente< Los Angeles, CA, USA, 1Sanofi Recherche,
Toulouse,France
Background: Combined aspirin (A) and ticlopidine (T) have been shown to
reduce stent thrombosis (ST), However,the efficacy of this approach in small
vessels under high-shear conditions is not known. Methods and Resu/ts:
Pigs (n= 6, wf23 + 2 kg) were pretreated with ticlopidine (T) (250 mg po/d/3
days) and aspirin (A) (10 mg/kg iv). Unpolished nitinol stents (n = 39) were
expandad to 2 mm diameter in a tubular perfusion chamber and interposed
in an ex-vivo porcine arferiovenous shunt. Stents were exposed to flowing
arterial blood at different shear rates (s–l) for 20 minutes. Animals were then
treated with clopidogrel (C) (5 mg/kg iv) and experiments were repeated.
Shear was regulated by altering the blood flow. ST was quantified by mea-
suring drythrombus weight. ADP-induced (2.5 mM) platelet aggregation (PA)
and bleeding time (BT) were estimated before and after C. C reduced PA by
45+ 5% and prolonged BT from 4 + 1 to 12 & 2* minutes (p c 0.01).
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Conclusions: Combined aspirin and ticlopidine do not inhibit acute throm-
bmis under conditions simulating high-risk scenting.Clopidogrel inhibits high-
shear mediated stent thrombosis resistant to aspirin and ticlopidine under
similar conditions.
9:15[7’7’1-41Radu~tioninThro~bogeniciWof~e,,u,ose
Polymer-Coated Stents by Immobilisation of
Plateiat-Targeted Urokinase
R.K. Aggarwal, DC. Ireland, MA. Azrinl, D.P.de Bono, A.H. Gerehlick.
Dapatiment of Cardiology, University of Leicestec UK, 1University of
Connecticut, Farmington, CT, USA
We have previously targeted urokinase (UK) to platelets by chemical con-
jugation with anti rabbit platelet GP llb/llla antibody (AZl) and shown the
enhanced platelet antiaggregatory effects of AZI-UK conjugate compared
with AZ1 antibody alone. This study aimed to evaluate the antithrombotic
properties of AZI-UK immobilised to cellulose polymer-coated stents (n =
22).
Mathods:Antithrombotic effects were determined by implanting the stents
into flow reduced, deeply injured iliac afteriea of New Zealand White tibbits
(n= 11). Each animal had a conjugate-immobilised stent in one vessel (Gr. 1)
and a base polymer control stent in the contrelateral vessel (Gr. H).Arterial
patency was determined after 2 hrs (n = 6 animals, acute group) and 28
days (n = 5 animals, chronic group). For the acute group, blood flow was
measured continuously using perivascular flowprobes (Tranaonice, NY) and
platelet adhesion determined using Ill Iridium Iabelled autologous piatetetS.
Total occlusion was defined as flow <0.5 mllmin for >10 rein; cyclic flow
variation (CFV) as return to flow >0.5 ml/min within 10 min. In the chronic
Gr. Acute group Chronicgroup
aPlatelets bCFV freq: C2 hrflow dn occluded ‘noccluded
(X107) (hr-i) (% baseline)
I 16.7 + 2.2 0 76,2 + 10,3 0 of 6 1 of 5
II 35.4 + 6.7 5.9 + 2.2 16.4 + 0.4 4 of 6 3 of 5
- - -. ----- . --” A ,
334A Ar5slwwls – ural
group,arterialocclusionwas determinedmacroscopicellyaftersacrifice.
f?esukare showninthe table.Comparedwithcontrolvessels(Gr. 11),ar-
terieswithconjugate-immobilisedstents(Gr. 1)hadsignificantlyIessaplatelet
deposition(P= 0.0003), fewer episodesof bCFV (P= 0.0011), highermean
C2-hourflow (P = 0.0002) and significantlyhigherarterialpatency‘rates (P
= 0.027).
Corrc/usion:Platelet-tSrgetSdurokinaeepassivelyimmobilisedtopolymer-
coetedstentemarkedlyreducestheirthrombogenicity.Suchdevicesmaybe
particularlyuaefulforanticoagulant-freestentinginsmallvessela. orforbailout
stentingand meritfurtherevaluation.
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n7715 A New Biodegradable Polylectic Acid CoronaryStent-Coating, Releasing PEG-Hirudin and a
Prostacycline Analog, Reduces Both Platelet
Activation and Plasmatic Coagulation
G.Schmidmaier, A. Stemberger1, E. Alt, M. Gawaz, F.-J.Neumann,
A. Sch6mig.1.Med. Klinik, Inst. for Exp. Surgery Germany 1 Tahnische
Universit.4tMOnchen,Germany
Experiencewithcoronarystentinghasdemonstratadthatadhesionofplasma
proteinsto the metallicstentsurfaceand plateletactivationlimitthe implant
effeotivenesaby meansof acuteand subacutethrombosis.We investigated
a new stentcoatingof polylacticacid (PLA) carrier(25 kDa) containing5%
polyethyleneglycol-hirudinand 1% prostacyclinanalog(PG12).Methods:7
mm metallicatents (n = 46) were tested coated vs uncoatedin a human
atasis model with the non-anticoagulatacfblood of healthy volunteers. After
5 min thrombusweight,aPTT, markersof”acfivatedcoagulation(thrombin-
antithrombin-complexesTAT 01and prothmmbinfragmentaF1–2), mllagen
inducedplateletaggregationand CD62p/CD4i expressionwere measured
andscanningelectronmicroacopyperformed.Ffesults:Uncoatedstentswere
completelycovered by a coagulationplug rich in fibrinand platelets.The
costed stents were practically free from thrombotic material.
Controlwithoutstent Uncoatedstent Coated etent
Thrombua(mg) 2.02 * 0.50”” 0.02+0.01
aPIT (sac) 29.87 *2.54 29,60 + 2.35** 58.7759.24
TAT 01(pmol/1) 5.92 +0.S4 25.52 A 4.45** 6.03+ 1.13
FI-2 lnmolll) 0.94+0.07 2.14+0.33** 0.99* 6.06
Piat~l~t”Agg~eg. (%) 92.13*4.24 90.62 *4.34*” 10.53* 0.33
AcDs2p 10.0s * 0.66 12.63 + 1.S4” 11.73+ 0.62
CD41a 146.56 + 5.S7 lS2.S3&4.78” 21.43+3.22
*P< 0.05,**P <0.001, Coatedvs uncOated Stent
Conclusion.’ Our results show that PIA stent coating releasing PEG-
hirudinandaprostacyclinanaloghasa significanteffectonbothplateletacti-
vationand plasmaticcoagulation,therebypreventingstentinducedthrombus
formation.
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m771 6 High-Shear Overridea the Antithrombotic Effects of
Aspirin on Stent Thrombosis
R. Makkar,F. Litvack,S. Kaul,H. Zeng, N. Eigler.Cedars-Sinai Medical
Center, Los Angeles, CA, USA
Shear at stent surfacea is affected by vessel size, blood flow, pre-existing
thrombusand adSCfuaCYofstentdeployment. Wetestedthe effiCSCYofaSPirin
(10 or 20 mg/kg iv) at different blood shear rates. Unpolished nitinol stents
(n= 46) were expanded to a diameter of 2 mm in a perfuaion chamber and
exposed to flowing arterial blood (n = 6 pigs) for 20 minutes in a porcine
arteriovenous shunt model of stent thrombosis. Shear was regulated by
altering the blood flow. Stent thrombosis was quantified by measuring dry
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thrombus weight. Data are mean + sd. Arachidonic acid (540 mM)-induced
Dlatelet aggregation was inhibited by 48 +5% (P < 0.01) and bleedin9 time
was mild~-pr;longed (360 * 50 vs. 200 + 30”secs; p = ns) with ASA 10
mg/kg. Higher doses of aspirin (20 mg/kg) simiiarly failed to inhibit ST (17 +
2 vs 19+ 1 mg for control, n =6; p = ns) at the highest shear.
Conclusion: ASA inhibits stent thrombosis at low but not at high shear
rates. In high-risk clinical situations characterized by high blood shear, ASA
alone may not provide sufficient antiplatelet activity.
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1772-1I predictor~ofsuccesaand~~jor~omPl,~ationsfor
Primary PTCA in Acute Myocardial Infarction
E.D. Grassman, S.A. Johnson, R.J. Krone. Loyo/a University Medical
Centec Maywood, IL, USA, Washington UniveraiV, St. Louis, MO, USA
Primaryangioplastyhas recentlybeen advocatedas a safe and moreeffec-
tivetreatmentthanthrombolytictherapyforacutemyocardialinfarction(AMI).
The Socieiy for Cardiac Angiography and Interventions (SCA&l) maintains
a regist~ for diagnostic and intetventional procedures. Primary angioplasty
for AMI in the laboratories contributing to the registw was reviewed, and
predictors of successful PTCA, in-hospital mortality, and emergency CABG
were identified. 4,366 PTCA procedures were performed for AMI without
prior thrombolytic therapy among 78,199 PTCA’S (5.6%). Lab volume, age,
sex, symptoms, intreaotiic balloon pump (IABP) use, prior AMI, prior CABG,
diabetes, hypertension, shock, moribund state, CHF, and prior PTCA of the
same aitewereanalyzed. The overall success rate was 91.5%, the in-hospital
morkelifyrate was 2.5%, and the rate of emergency CABG was 3.&’o. These
are all similar to other published series. Higher PTCA volume and lower age
wera predictive of successful PTCA using multivariable logistic regression
analysis, while an IABP in place, shock, and moribund state had negative
predictive effects (p< 0.05). Unsuccessful PTCA, shock, and moribund state
were predictive of in-hospital death (p < 0.05). Unsuccessful PTCA, the ab-
sence of hypertension,and absence of CHF were predictiveof emergency
CABG (p < 0.05).
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1772-21Nine-yearoutcomeofpatiente”nder~oin9
Percutaneous Transluminal Coronary Angioplaety
for Acute Myocardial Infarction: Repo~ from the
1985-1986 NHLBI PTCA Regiatry
S.T. Lee, D.O. Williams, C.R. Cannan, K.E. Kip, S.F. Kelsey, K.M. Detre.
Rhode /s/and Hospital, Brown University Providence, RI, USA
Percutaneoustransluminal coronatyangioplasty (PTCA)isan effeofivemeans
of achieving reperfusion in patients with acute myocardial infarction, but the
long-term outcome of this therapy is unknown. Accordingly, we foilowed the
clinical status of 1320 consecutive PTCA patients without history of Ml (no
Ml), 619 patients with Ml >30 days prior to PTCA (remote Ml), 373 patients
with Ml 46 hours to 30 days prior to PTCA (recent Ml), and 119 patients
with Ml within 46 hours of PTCA (acute Ml). The in-hospital mortalities were
no Ml 0.8Y0, remote Ml 1.0%, recent Ml 1.9%, and acute Ml 9.2% (p <
0.001). After a median of 9.0 years of follow-up, the risk of subsequent Ml or
bypass surgery did not differ by pre-procedural Ml,status with the exception
that acute Ml patients had less repeat PTCA (20.9$’.) than the other three
groups (range 31.5%-42.7%, p < 0.01). Crude nine-year mortality, however,
was higheat in the acute Ml patients (41.8Yo)when compared with recent
Ml (22.8%), remote Ml (25.1%), and no Ml patients (17.9%, p c 0.001).
After adjusted multivariate analysis, Ml within 48 hours of PTCA remained an
independent predictor of nine-year mortality (relative risk= 1.75, p c 0.01).
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